|
Characteristic
|
Total (cases)
|
Pertuzumab group [cases (%)]
|
Control group [cases (%)]
|
|---|
|
Total
|
163
|
82
|
81
|
|
Age
|
|
< 65 years
| |
61 (74.4)
|
62 (76.5)
|
|
≥ 65 years
| |
21 (25.6)
|
19 (23.5)
|
|
Sex
|
|
Male
|
130
|
59 (72.0)
|
71 (87.7)
|
|
Female
|
33
|
23 (28.0)
|
10 (12.3)
|
|
Disease measurability
|
|
Measurable
|
144
|
74 (90.2)
|
70 (86.4)
|
|
Non-measurable
|
19
|
8 (9.8)
|
11 (13.6)
|
|
ECOG PS
|
|
0
|
47
|
24 (29.3)
|
23 (28.4)
|
|
1
|
116
|
58 (70.7)
|
58 (71.6)
|
|
Histological subtype (Lauren classification)
|
|
Diffuse
|
16
|
9 (11.0)
|
7 (8.6)
|
|
Intestinal
|
144
|
71 (86.6)
|
73 (90.1)
|
|
Mixed
|
3
|
2 (2.4)
|
1 (1.2)
|
|
Primary site
|
|
Gastroesophageal junction
|
33
|
21 (25.6)
|
12 (14.8)
|
|
Stomach
|
130
|
61 (74.4)
|
69 (85.2)
|
|
Number of metastatic sitesa
|
|
1–2
|
139
|
68 (82.9)
|
71 (88.8)
|
|
> 2
|
23
|
14 (17.1)
|
9 (11.3)
|
|
HER status
|
|
IHC2+ and ISH+
|
31
|
14 (17.1)
|
17 (21.0)
|
|
IHC3+
|
132
|
68 (82.9)
|
64 (79.0)
|
|
Prior gastrectomy
|
|
Yes
|
47
|
23 (28.0)
|
24 (29.6)
|
|
No
|
116
|
59 (72.0)
|
57 (70.4)
|
- ITT intention to treat; ECOG PS Eastern Cooperative Oncology Group performance status; HER2 human epidermal growth factor receptor 2; IHC immunohistochemistry; ISH in situ hybridization
- aOne patient in the control group did not have data on the number of metastatic sites available
